ALXO (ALX Oncology Holdings) Other Current Receivables: $1.17 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ALXO ALX Oncology Holdings Inc ALXO
31 GF Score
Price $2.03
! 3 Warning Signs
View Full Analysis

What is ALX Oncology Holdings Other Current Receivables?

ALX Oncology Holdings ALXO +2.27% 31 Other Current Receivables is $1.17 Mil as of Jun. 2026. GuruFocus rates ALXO with a GF Score™ of 31/100. The stock has 3 warning signs investors should review.

ALX Oncology Holdings's Other Current Receivables for the quarter that ended in Jun. 2026 was $1.17 Mil.

ALX Oncology Holdings's quarterly Other Current Receivables increased from Dec. 2025 ($0.30 Mil) to Mar. 2026 ($0.99 Mil) and increased from Mar. 2026 ($0.99 Mil) to Jun. 2026 ($1.17 Mil).

ALX Oncology Holdings's annual Other Current Receivables increased from Dec. 2023 ($0.00 Mil) to Dec. 2024 ($0.89 Mil) but then declined from Dec. 2024 ($0.89 Mil) to Dec. 2025 ($0.30 Mil).

ALX Oncology Holdings Other Current Receivables Related Terms

ALX Oncology Holdings Other Current Receivables Historical Data

* Premium members only.

The historical data trend for ALX Oncology Holdings's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ALX Oncology Holdings Other Current Receivables Chart

ALX Oncology Holdings Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Receivables
Get a 7-Day Free Trial 0.00 0.00 0.00 0.89 0.30

ALX Oncology Holdings Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.67 0.40 0.30 0.99 1.17
ALXO
31GF Score
ALX Oncology Holdings Inc ALXO
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ALX Oncology Holdings Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of $1.17 Mil mean?
ALX Oncology Holdings (ALXO) has a Other Current Receivables of $1.17 Mil as of Jun. 2026. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on ALX Oncology Holdings and its competitors.
Is ALX Oncology Holdings' Other Current Receivables too high?
ALX Oncology Holdings' current Other Current Receivables is $1.17 Mil. Overall, ALX Oncology Holdings has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does ALX Oncology Holdings' Other Current Receivables compare to CYDY and BCYC?
ALX Oncology Holdings' Other Current Receivables of $1.17 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Biotechnology company?
A good Other Current Receivables depends on the Biotechnology industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on ALX Oncology Holdings and its competitors. ALX Oncology Holdings's current Other Current Receivables is $1.17 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ALX Oncology Holdings stock overvalued right now?
ALX Oncology Holdings (ALXO) has a current Other Current Receivables of $1.17 Mil. The current Other Current Receivables is $1.17 Mil. ALX Oncology Holdings' overall GF Score™ is 31/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For ALX Oncology Holdings (ALXO), the current Other Current Receivables is $1.17 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

ALX Oncology Holdings Business Description

Address 323 Allerton Avenue, South San Francisco, CA, USA, 94080
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
31GF Score

Get the complete analysis for ALXO

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.03
Price